Gastric bleeding and benorylate, a new aspirin.
Benorylate (4-acetamidophenyl 2-acetoxybenzoate) is a new esterified aspirin preparation whose antirheumatic properties are reported to be as good as those of aspirin. Gastrointestinal blood loss, measured with (51)Cr-labelled red cells, during benorylate therapy was compared with that during therapy with soluble aspirin in 15 subjects, a simplified crossover procedure being used. Mean blood loss during benorylate therapy was 1.7 ml/day which was significantly less than that during therapy with soluble aspirin (5.1 ml/day; P <0.001). In 12 of the 15 patients blood loss with benorylate was less than 2.5 ml/day. Benorylate appears to be a definite improvement on current formulations of aspirin and should be a useful drug for the treatment of patients with chronic rheumatic disorders.
D000083:Acetanilides / Q000009:adverse effects; D000085:Acetates / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000009:adverse effects*; D002859:Chromium Isotopes; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005243:Feces; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009780:Occult Blood; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012459:Salicylates / Q000009:adverse effects*; D012995:Solubility
D000083:Acetanilides; D000085:Acetates; D000700:Analgesics; D002859:Chromium Isotopes; D012459:Salicylates